Aldeyra Therapeutics to Present at the OIS Virtual Public Company Showcase on July 16, 2020
July 13 2020 - 4:05PM
Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today
announced that Todd C. Brady, M.D., Ph.D., President and Chief
Executive Officer, will discuss the company’s clinical programs in
anterior and posterior ocular disease as part of the Ophthalmology
Innovation Summit’s Virtual Public Company Showcase on Thursday,
July 16, 2020. Dr. Brady’s presentation is scheduled for 1:40 to
1:50 p.m. ET.
As part of the Showcase, Dr. Brady also will participate in the
Ophthalmology Outlook Panel moderated by Emmett T. Cunningham Jr.,
M.D., Ph.D., MPH, Senior Managing Director for Blackstone Life
Sciences. The panel discussion is scheduled for 2:20 to 3:00 p.m.
ET.
A webcast of Dr. Brady’s presentation and the Ophthalmology
Outlook Panel will be available on the investor relations page of
the company’s corporate website at https://ir.aldeyra.com or
https://hopin.to/events/ois-virtual-public-company-showcase.
Registration is required; suggested log-in is at least 10 minutes
prior to the scheduled event. After the webcast, the event will
remain archived on the Aldeyra Therapeutics website for 90
days.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company
focused on the development of novel therapies with the potential to
improve the lives of patients with immune-mediated diseases. Two of
the company’s lead compounds, reproxalap and ADX-629, target
reactive aldehyde species (RASP), which are elevated in ocular and
systemic inflammatory disease, leading to elevated levels of
cytokine release via activation of a broad array of inflammatory
factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Reproxalap is being evaluated in Phase 3 clinical trials in
patients with dry eye disease and allergic conjunctivitis. The
company’s clinical pipeline also includes ADX-2191, a dihydrofolate
reductase inhibitor in Phase 3 testing for proliferative
vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2
testing for COVID-19 and ovarian cancer. For more information,
visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook,
and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200713005614/en/
Corporate Contact: David McMullin Aldeyra Therapeutics,
Inc. Tel: 781-761-4904 ext. 218 dmcmullin@aldeyra.com
Investor & Media Contact: Scott Solomon Sharon
Merrill Associates, Inc. Tel: 617-542-5300
ALDX@investorrelations.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2023 to Apr 2024